Objectives: To understand overview and evaluate the pricing & reimbursement policies of USA, UK, Germany, Japan and France. Methods: A desk research was carried out. Data was collected from published materials, such as published articles, government publications, press releases, and news articles, online portals of regulatory agencies and relevant keyword searches. This data was then evaluated on the basis of several parameters. Results: Japan follows international reference pricing where it gains the reference from US, UK, Germany, and France. France follows ASMR evaluation and then it negotiates the price with company. In USA, there is a free pricing policy. USA has a robust reimbursement system under Medicare, Medicaid and CHIP. There is mutual understanding between companies and payers. Therefore, companies keep the price controlled. In UK, there is Value Based Pricing for branded and Reference to market prices in case of generics. In Germany, there are different pricing policies for different types of products. However the sponsor is free to set the price of a product initially for a period of 12 months. Conclusions: Pricing is expected to be based on an equitable, transparent and lucid system. Pricing policies should vary country to country depending upon various factors like economy, population and patient burden.